FenoMark Diagnostics

Executive Summary

FenoMark Diagnostics is a Swedish private company founded in 2016, headquartered in Gothenburg, that leverages mass spectrometry-based proteomics to develop clinically relevant diagnostic solutions. The company collaborates with world-leading experts to create capabilities for analyzing patient samples, aiming to address pressing clinical needs with a focus on individualized patient care. Despite being in a competitive diagnostics landscape, FenoMark's specialized approach in proteomics positions it for potential breakthroughs in precision medicine. However, the company has not disclosed funding rounds, valuation, or commercial products, indicating it may still be in early or development stages. With no publicly available pipeline or regulatory milestones, the near-term outlook is uncertain, but the technology holds promise for applications in oncology, neurology, and other fields where protein biomarkers are critical.

Upcoming Catalysts (preview)

• TBDAnnouncement of Strategic Partnership or Collaboration60% success
• TBDCompletion of a Series A or Seed Funding Round50% success
• TBDPublication of Clinical Validation Study Results40% success